<DOC>
	<DOCNO>NCT00410761</DOCNO>
	<brief_summary>The purpose study learn hereditary sporadic medullary thyroid cancer patient , treat ZD6474 , react drug , happen ZD6474 human body , side effect ZD6474 , ZD6474 decrease prevent growth tumor .</brief_summary>
	<brief_title>An Efficacy Study Comparing ZD6474 Placebo Medullary Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<criteria>Confirmed diagnosis unresectable , locally advanced metastatic hereditary sporadic Medullary Thyroid Cancer . Presence measurable tumor Able swallow medication Major surgery within 4 week randomization Last dose prior chemotherapy receive less 4 week prior randomization Radiation therapy within last 4 week prior randomization ( exception palliative radiotherapy ) Brain metastases spinal cord compression , unless treat least 4 week first dose stable without steroid treatment 10 day Significant cardiac event Previous ZD6474 treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ZD6474</keyword>
	<keyword>MTC</keyword>
	<keyword>Hereditary Medullary Thyroid Cancer</keyword>
	<keyword>Sporadic Medullary Thyroid Cancer</keyword>
	<keyword>Medullary Thyroid Cancer</keyword>
</DOC>